Announced
Financials
Sources
Tags
Private
Cross Border
Acquisition
Friendly
Pending
Majority
Single Bidder
United States
biotechnology
clinical trials
Biotechnology
Synopsis
Grifols, a global producer of plasma-derived medicines, agreed to acquire the remaining 55% stake in Alkahest, a Silicon Valley-based biotechnology company, for $146m. "We are excited to join forces with Grifols, an industry leader in plasma-derived medicines, to realize our shared vision and mission of delivering innovative medicines for age-related diseases on an ambitious scale," Karoly Nikolich, Alkahest CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.